Next Article in Journal
Recent Insights into the Control of Human Papillomavirus (HPV) Genome Stability, Loss, and Degradation
Next Article in Special Issue
Myogenic Precursors from iPS Cells for Skeletal Muscle Cell Replacement Therapy
Previous Article in Journal
NLRP3 Inflammasome and Pathobiology in AMD
Previous Article in Special Issue
Design of a Tumorigenicity Test for Induced Pluripotent Stem Cell (iPSC)-Derived Cell Products
Article Menu

Export Article

Open AccessCommentary

The State of Play with iPSCs and Spinal Cord Injury Models

School of Anatomy, Physiology and Human Biology, The University of Western Australia, Crawley, Western Australia 6009, Australia
Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain
Faculty of Medicine, The University of Sydney Medical School, Division of Pediatrics and Child Health, Westmead Children's Hospital, Sydney 2010, Australia
School of Anatomy, Physiology and Human Biology, and the Harry Perkins Institute for Medical Research (CCTRM), The University of Western Australia, Western Australia 6009, Australia
Author to whom correspondence should be addressed.
Academic Editor: David T. Harris
J. Clin. Med. 2015, 4(1), 193-203;
Received: 8 October 2014 / Accepted: 8 December 2014 / Published: 14 January 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
PDF [59 KB, uploaded 14 January 2015]


The application of induced pluripotent stem cell (iPSC) technologies in cell based strategies, for the repair of the central nervous system (with particular focus on the spinal cord), is moving towards the potential use of clinical grade donor cells. The ability of iPSCs to generate donor neuronal, glial and astrocytic phenotypes for transplantation is highlighted here, and we review recent research using iPSCs in attempts to treat spinal cord injury in various animal models. Also discussed are issues relating to the production of clinical grade iPSCs, recent advances in transdifferentiation protocols for iPSC-derived donor cell populations, concerns about tumourogenicity, and whether iPSC technologies offer any advantages over previous donor cell candidates or tissues already in use as therapeutic tools in experimental spinal cord injury studies. View Full-Text
Keywords: spinal cord injury; induced pluripotent stem cells; transplantation spinal cord injury; induced pluripotent stem cells; transplantation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Hodgetts, S.I.; Edel, M.; Harvey, A.R. The State of Play with iPSCs and Spinal Cord Injury Models. J. Clin. Med. 2015, 4, 193-203.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top